People

Benjamin Eckhardt
Benjamin J. Eckhardt, MD, MS
NYU School of Medicine, Department of Medicine, Division of Infectious Diseases and Immunology - Assistant Professor Medicine
Bellevue Hospital, Department of Medicine, Division of Infectious Diseases and Immunology
Email: benjamin.eckhardt@gmail.com
Education
MD, Albert Einstein College of Medicine
MS, Clinical Epidemiology and Health Services Research, Cornell University Graduate School of Medical Sciences
BS, Biological and Environmental Engineering, Cornell University
Research Interests
Hepatitis C, HIV, People who inject drugs, Harm reduction
BIO
Benjamin Eckhardt received his MD degree from Albert Einstein College of Medicine and  Internal Medicine training at NYU within the Primary Care Program. After completing residency, he worked in Rwanda for Partners In Health/Inshuti Mu Buzima with a clinical appointment at Brigham and Women’s Hospital and Harvard Medical School. He returned to New York to complete his fellowship training in Infectious Diseases at Weill Cornell Medical College while concurrently receiving a MS in Clinical Epidemiology and Health Services Research. He joined the faculty at NYU/Bellevue in 2016 with a clinical focus in HIV and hepatitis management.

Dr. Eckhardt’s research interest focuses on evaluating models of care to facilitate access, engagement, and retention of active injection drug users in HCV treatment and care.
Projects
Principal Investigator, HCV – Source Patient Identification and Group Overlap Treatment. Completed
Publications

Recent

Gispen F, Mao J, Karan K, Bao Y, Levander XA, Wethington E, Eckhardt BJ, Sustersic B, Kapadia SN (2026).
Outpatient antibiotic fills and 30-day readmission following patient-directed discharge in drug use-associated infective endocarditis in a national Medicaid cohort
Clinical Infectious Diseases [Epub 2026 Oct 14]. doi: 10.1093/cid/ciag649.

Nolan NS, Sherbuk J, Maximos M, Egbert S, Cappiello M..., Eckhardt B, ...Baden R (2026).
Guidelines for prevention and management of complications of injection drug use: A WikiGuidelines group consensus statement
American Journal of Medicine [Epub 2026 Aug 27]. doi: 10.1016/j.amjmed.2026.07.049.

Finbraten AK, Chin CL, Seetharaman M, Hutchings K, Eckhardt BJ, Schackman BR, Kapadia SN (2025).
Providers’ perspectives on implementation of low-threshold HCV treatment in New York State: A qualitative study
Open Forum Infectious Diseases, 12 (4), ofaf184. doi: 10.1093/ofid/ofaf184. PMCID: PMC12019634.

Lee CSJ, Mateu-Gelabert P, Aponte-Melendez Y, Fong C, Kapadia SN, Smith M, Marks KM, Eckhardt B (2024).
Reduced injection risk behavior with co-located hepatitis C treatment at a syringe service program: The accessible care model
PLoS One, 19 (8), e0308102. doi: 10.1371/journal.pone.0308102. PMCID: PMC11361571.

Mateu-Gelabert P, Pratt S, Guarino H, Hallack R, Fong C, Eckhardt B (2024).
HCV prevalence and phylogenetic characteristics in a cross-sectional, community study of young people who inject drugs in New York City: Opportunity for and threats to HCV elimination
Health Science Reports, 7 (7), e2211. doi: 10.1002/hsr2.2211. PMCID: PMC11217018.

Dr. Eckhardt's NYU Langone Profile